Acceptable TakeOverPrice, page-67

Mate not sure I entirely agree:

In relation to 1. - This will depend will it not on whether BIT225 has a universal action on the way a virus infects cells, albeit different virus' will likely need different dosage, timing of dosage etc. The point of BIT225 is it might have applications against a vast number of virus' being the first of its type in a new class of drugs, as opposed to different drugs within a class being used on different virus'.

In relation to 2.- On what basis can you conclude this? The way in which Bit 225 affects a particular virus/ cohort might well have analogous statistical importance, especially if there is a universal action in the way the drug works. We are not privy yet to the headline data and interpretation of it and there might very well be data from different cohorts that have a common denominator of significant commercial value.

In relation to 3. - I don't know how we can say we cannot add data together to draw conclusions. I agree we should not do so to draw meaningless conclusions but scientists working on this might draw central conclusions from data of the varied cohorts and virus' that have been tested. To my mind BIT225 seems to have a universal action on virus pathogens as a starting point. We shareholders do not have the data and therefore enough particular insight to say data cannot be added together to draw conclusions, for example identifying common outcomes, reactions etc across different cohorts.

Further, BIT225 may well be a cure for HCV, but at this juncture it might be of little consequence that other 'other cures' have gotten through phase 3 trials to commercialisation ahead of BIT225. For those who undergo treatment to cure HCV it can be a drawn out process with serious side effects so significant some people need to abandon the treatment. It might come to be that BIT225 offers a simpler treatment regime with less or no significant side effects putting it at the forefront of treatment for HCV, the commercial significance being clear. Simply put, BIT225 might see earlier current treatments rapidly become obsolete.

In my opinion if the headline data is positive enough there will absolutely be phase 3 trials, possible expedited with the FDA's blessing and it is at that point BP would be looking to take a strong commercial involvement rather than risk sitting back and waiting for final outcomes in case someone else gets in on the action before they do.

IF headline data is positive enough I reckon an announcement will come out shortly thereafter - or possibly at the same time- of a partnership with BP to see completion through to revenue and beyond... Cheers

Note: My wife will tell you I am right on any topic less than half of the time.